Research
A Swedish Vaccine Against Alzheimer's
Article no. 13 · March 23, 2026 · Updated September 20, 2026 ·
While the world discusses expensive antibody treatments, something that could be a completely different approach is being developed in Sweden: a vaccine against Alzheimer's disease.
The Gothenburg-based biotech company Alzinova has developed a vaccine candidate called ALZ-101.
This is not a preventive vaccine given to healthy people. Instead, it is a therapeutic vaccine for people who already have the disease.
The idea is simple but powerful:
The vaccine trains the body's immune system to recognize and attack the toxic amyloid-beta oligomers that are believed to damage brain nerve cells in Alzheimer's.
Unlike current antibody treatments, which often require repeated infusions in hospitals, a vaccine can in principle be given a few times a year, causing the body to produce its own antibodies.
The first clinical studies have shown that the vaccine is well-tolerated and can induce an immune response. Clinical trials are now continuing to investigate whether the treatment can also slow the progression of the disease.
If this strategy works, it could be both simpler, cheaper, and more long-term than current treatments.
If this leads to an approved medicine, it will take so long that I will not benefit from this vaccine. The development of new medicines takes a long time.
Facts about clinical research
Preclinical research
Laboratory tests and animal studies to investigate safety and biological effect.
Time required: approximately 3–5 years.